SCNX Q3'26 Earnings: EPS estimate is (1.57) USD

Scienture Holdings (SCNX) will report Q3'26 earnings on November 12. Analysts expect revenue of $1.22M and an EPS loss of $1.57. Details are available on the company's Financials page.

Original reporting
Published Nov 11, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 12:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SCNX Q3'26 Earnings: EPS estimate is (1.57) USD — source image
Decision brief

The 30-second read

$SCNXBearishLow
01

Why it matters

The projected loss may set expectations for a price decline, but any beat could trigger a rapid rebound.

02

Market read

The estimate is the first disclosed figure for this quarter, offering modest trading relevance for short‑term positioning.

03

What to watch

Potential hidden catalysts such as upcoming trial data or partnership announcements not reflected in the estimate.

Relevance 5/10Novelty 5/10Timing: pre‑market ahead of Nov 12 earnings release

Background

SCNX is a biotech firm with a history of volatile earnings. The article provides only the upcoming earnings estimate, not actual results.

Company-level read

Ticker impact

$SCNXBearishMedium confidence
Context

SCNX (Scienture Holdings) is scheduled to release its Q3'26 earnings on Nov 12 with an estimated EPS of (1.57) USD, indicating a projected loss.

Expected impact

likely pressure as investors price in the projected loss

Evidence & confidence

A projected loss of $1.57 per share is material for a small‑cap issuer and may trigger sell‑offs before the earnings release.

Market effects

The estimate may affect peer biotech and specialty pharma stocks as investors reassess sector earnings expectations.

Limited to US‑listed small‑cap market; no broader regional effect.

Minimal global impact beyond niche investors tracking SCNX.

Counterpoint

If the company can beat the bleak estimate, the stock could rally sharply on surprise upside.

Key entities

  • Scienture Holdings, Inc.

    Issuer of the upcoming Q3'26 earnings estimate.

Related articles

$SCNXMed

Scienture Holdings, Inc. (SCNX): Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential…

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli ™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additi

$SCNXMed

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base Q2 2026 Operat

$SCNXMedAI 8/10

Scienture Holdings, Inc.: SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

Scienture Holdings (NASDAQ: SCNX) reported Q2 2026 results: revenue rose about 510% sequentially to $343,639 from $56,325 in Q1. Q2 gross margin was about 97.7%. Operating loss improved about 48% to ~$2.7M and net loss narrowed about 58% to ~$2.8M. The company began commercial launch of REZENOPY and cited USPTO patent grants and expanded payer coverage.

$SCNXMedAI 8/10

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

Scienture (NASDAQ:SCNX) says it has commercially launched REZENOPY, a 10 mg naloxone hydrochloride nasal spray, after fulfilling initial U.S. wholesaler purchase orders and starting nationwide distribution. The company cites IQVIA data for a $143 million U.S. naloxone market (9.8 million units) and says payer coverage could exceed 100 million lives via GPO access to 5,000+ facilities. No revenue guidance was provided.

$SCNXMed

Scienture Announces Commercial Inventory Readiness For REZENOPY Naloxone Nasal Spray; Stock Up

Scienture Holdings (SCNX) said it completed manufacturing commercial launch inventory for REZENOPY naloxone nasal spray 10 mg and will start shipments to U.S. wholesalers in July, with broad availability expected in August. The company cited IQVIA data valuing the U.S. naloxone market at about $144 million annually and said payer access could cover over 100 million lives.